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Abstract Recent studies have suggested that benzalkonium chloride (BKC), an antimicrobial agent used as a preser-
vativeinnasalsprays, lacksdeleteriouse¡ectsonthenasalciliatedepithelium.Otherdata, includingrecent invivo¢ndings,
suggestthat BKCmay, in fact, produce adverse clinical e¡ects onhumannasal tissue, including the aggravation of rhinitis
medicamentosa.Toxic e¡ects have also been reported. In light of the discrepancy between negative results and studies
suggesting no safety concerns, we consider the possibility of problems in the design and methodology of some of the
studies and inthe interpretation of results.Clearly, further research iswarranted to clarify the signi¢cance of con£icting
¢ndings. In themeantime, without conclusive data regarding BKC and the possibility of harmful e¡ects, the use of nasal
formulationswithout BKCmight be a reasonable alternative.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1127, available online athttp://www.idealibrary.comon
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Benzalkonium chloride (BKC) is a quarternary ammo-
nium compound commonly used to prevent bacterial
contamination and to preserve pharmacological activity
in topical aqueous drops and sprays. Although ophthal-
mic mucositis and contact dermatitis resulting from the
presence of BKC in topical solutionshavebeen documen-
ted (1,2), investigators haverecently concluded that inclu-
sion of the preservative BKC in nasal sprays does not
yield any adverse biological e¡ects in vivo (3,4). In studies
conducted in both laboratory animals and perennial
allergic rhinitis patients (3,4), the nasal mucosa was
shown to be largely una¡ected as assessed primarily by
morphological indices.However, recent studies concern-
ing the pathophysiology of rhinitis medicamentosa
clearly indicate an adverse biological role of BKC in vivo
(5^7). These data are consistent with the numerous in
vitro studies characterizing the adverse e¡ects of BKC
on nasal mucociliary transport and nasal histology
(8^15). Thus, the objective of this article is to reassess
the hypothesis that BKC lacks deleterious e¡ects in vivo.Received18 August 2000 and accepted in revised form 7 April 2001
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In a study conducted in laboratory animals, Ainge et al.
failed to show any deleterious e¡ects of corticosteroid-
containing nasal sprays on the nasal epithelium (3). The
objective of the study was to examine the e¡ect of re-
peated exposure of normal cynomolgus monkeys and
rats to BKC-containing steroid formulations, namely, £u-
ticasone propionate and beclomethasone dipropionate
nasal sprays.
Cynomolgus monkeys were treated with £uticasone
propionate (0?05%w/v) containing 0?02%BKC for 28days
(860?1mlday71by intra-nasal spray).Rats were treated
with beclomethasone dipropionate (0?2%) nasal spray
containing 0?01% BKC for 28 days (1hday71 via inhala-
tion). Control conditions included either a 5% glucose
spray for monkeys or air inhalation for rats. At the con-
clusion of the treatment period, animals were sacri¢ced
and the nasal mucosa examined by light microscopy. In
addition, nasal mucosal tissues were sectioned for scan-
ning and transmission electron microscopy to allow
for counting of ciliary nasal cells and study of ciliary cell
ultrastructure.
The number of ciliated cells per mm of turbinate was
not di¡erent in either monkeys or rats when the group
administered BKC-containing steroid was compared to
control.The respiratory epithelia covering the turbinate
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Likewise, no di¡erence in nasal mucosal ultrastructure
(i.e. nuclei, mitochondria, rough and smooth endoplas-
mic reticula, lysosomes, cytoplasmic vacuoles,microvilli,
cilia and their basal bodies) was observed. In summary,
no changes in morphological features were noted in the
presence of BKC.
However, the signi¢cance of these negative ¢ndings
maybe limited for several reasons (16,17).First, the biop-
sies of the samples were restricted to the turbinate
epithelium (i.e. right inferior turbinate, monkeys; inter-
mediate turbinate, rats) and, therefore, the investigators
may have failed to detect benzalkonium-induced struc-
tural changes in other regions of the nasal mucosa (17).
Other studieshave found BKC tobeharmful to other re-
gions of the nasal mucosa (16). Second, the studies were
also conductedwith inhaled sprays (i.e.metering/atomiz-
ing pumps, in monkeys; inhalation chamber using a glass
concentric atomizer fed by a peristaltic pump, in rats),
whichmayhave lessened the insult accompaniedbypres-
surized sprays. Ainge et al. (3) exposed the subjects to
more BKC than typical decongestants usually contain.
While the normal amount of sprays administered per
nostril per day is 4, the monkeys received 8 sprays per
day. The concentrations of BKC administered to the
monkeys were lower than patients typically receive
(0?01% vs. 0?02%). However, the nasal epithelium of the
rats andmonkeys was exposed to BKC continuously for
1h a day, which is much greater exposure than patients
typically receive. The absence of morphological damage
corroborates previous results revealing no damage to ci-
liated cells in patients receiving £uticasone propionate
aqueous nasal spray or beclomethasone dipropionate
aqueous nasal spray.
In contrast, di¡erent parts of the nasal bed may have
varying reactions to BKC toxicity and di¡erent degrees
of contact with the nasal spray (18). For example, the
anterior area of the nasal septum, the tips of the inferior
andmiddle turbinate, and the anterior aspect of a polyp
are more directly challenged by the impact of the nasal
spray and, therefore, are exposed to greater concentra-
tions of preservative (18).Third, since adequate controls
with BKC alone (i.e. 5% glucose, monkeys; air, rats) were
not performed, it is possible that the corticosteroid
masked the deleterious e¡ects of BKC. Fourth, this
study was strictly structural and did not consider possi-
ble adverse functional e¡ects of BKC. Fifth, it is unclear
as towhether the results of this animal trial are transfer-
able to humans. In humans, the anterior parts of thenose
are the areas where considerable deposition of inhaled
substances occurs. Also, the lack of change inmorpholo-
gical features in the presence of BKC may be due
to the pH of the solution (3).Van de Donk et al. (9) sug-
gested that reducing the pH of BKCmay signi¢cantly de-
crease ciliary movement of guinea pig trachea. In the
study, the duration of ciliary movement decreased from1?33h to 1h when the BKC solution pH was reduced
from 7?4 to 6?0.
In vivoHuman Studies
BKCwas also shown to be nontoxic to nasal mucosa in
patients with perennial allergic rhinitis in a study by
Braatetal. (4).The objective of this study was to examine
the e¡ects of BKC on the human nasalmucosa in a popu-
lation of patients with perennial allergic rhinitis.
The study consisted of a single-center, double-blind
trial of 22 patients with perennial allergic rhinitis who
were also allergic to house dust mites (as con¢rmed by
skin-prick test). After a 2-week placebo treatment peri-
od, patients were randomized to receive one of the fol-
lowing twice daily: a nasal spray of 200mg £uticasone
propionate containing 0?02% BKC, a placebo aqueous
spray of 0?02% BKC, or placebo aqueous nasal spray.
Patients were assessed at 2 weekly intervals during
treatment and 2 weeks after treatment by anterior rhi-
noscopy for turbinate swelling, crushing, bleeding,
mucosa color and nasal secretions. Saccharine transport
time was determined to assess mucociliary clearance.
Prior to treatment and 6weeks after treatment, twona-
sal biopsies were taken from each patient 2 cm behind
the anterior tip of the inferior turbinate for microscopy.
Light microscopy was performed to measure mucosal
length and the number of ciliated epithelial cells. Scan-
ning electron microscopy was conducted to determine
the ratio of ciliated cells to nonciliated cells.Transmission
electron microscopy was used to examine the ultra-
structure of the ciliated epithelial cells.
An improvementwas noted formucosal color and se-
cretions in the group of patients assigned £uticasone
with BKC, but no change was noted with BKC alone.
No di¡erence was noted for any of the patient groups
with reference to the ciliary transport times assessed
at biweekly intervals by the saccharine clearance test.
The number of ciliated cells varied widely but was also
unchanged between patient groups. Decreased inci-
dence of edema and in£ammatory cell in¢ltration was
noted in patients treated with £uticasone, while BKC
appeared to have no e¡ect on this parameter.
Despite the existence of somepathological features in
all patients studied, transmission and scanning electron
microscopy did not show BKC to have adverse e¡ects.
Common pathological features observed in biopsies in-
cluded the presence of numerous cytoplasmic vacuoles,
very electron-dense and swollen mitochondria, and
swollen smooth endoplasmic reticulum. Importantly,
the cilia appeared similar in all treatment groups, with
the classic 9+2 con¢guration of microtubules present.
Based on scanning electron microscopy, data was
marred (i.e. varying number of ciliated cells) by residual
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was una¡ected by BKC.
As noted for the previous study, weaknesses limit the
signi¢cance of the Braat study (16,17). First, the biopsies
of samples were limited to the inferior turbinates and
may not re£ect the deposition and subsequent e¡ects
on other nasal regions. However, previous studies such
as that by Newman et al. (19) demonstrated chief deposi-
tion in the anterior part of the nose in10 normal subjects
usingnasalpump sprays.Within 30min of administration,
a mean 56% of the dose remained at the initial site of de-
position, while the remainder (44%) of the dose cleared
to the nasopharynx (19). Second, signi¢cant variation
was observed in the patients studied under control con-
ditions, particularly with regard to morphological data,
such that any changes ascribed to BKCwere di⁄cult to
detect. Third, the patient population under study was
su¡ering from perennial allergic rhinitis, whereby pro-
tection a¡orded by excessive mucus production possibly
obscured any adverse biological e¡ects of BKC.This pro-
tective e¡ectwas observed in a studyby Stanleyetal. (11)
who suggested that the lack e¡ect of BKC on ciliarybeat
frequency ormucociliary clearancewas the result of the
e¡ects of nasalmucus.
A third in vivo study by McMahon et al. attempted to
determine the immediate and short-term e¡ect of BKC
in an intranasal corticosteroid spray on human nasalmu-
cosa in vivo (20). In this study, the authors assessedmean
saccharine clearance time, acoustic rhinometry, and
ciliary beat frequency prior to and after 2 weeks of ther-
apy in normal volunteers randomized to receive saline,
£uticasone propionate aqueous nasal spray, or placebo.
A10-min exposure to BKC in 34 subjects led to a signi¢-
cant increase in the mean clearance time (762?7+
459 sec) versus that observed with saline alone
(620+437 sec). However, a double-blind multi-dose
study comparing saline solution, £uticasone propionate
plus BKC, and BKC alone, administered for 2 weeks at 2
pu¡s per day, showed no di¡erences in saccharine clear-
ance or in any of the variables tested.
The initial results of the studyöthat the BKC solution
caused an immediate increase in mucociliary clearance
timeöweremost likely due to ciliary dysfunction result-
ing from the application of BKC (20). Although the toxic
e¡ects of BKCwere not apparent in themultidose study,
both the initial test and the 2-week study included only
normal individuals; patients su¡ering from rhinitis who
had used a topical nasal treatment in the 2 weeks prior
to the study were not tested. In patients with rhinitis, it
is important to note that the capacity of themucociliary
defense systemmaybe reduced as a result of the disease
itself. Patients with rhinitis, therefore, may be more
prone to the adverse e¡ects of BKC than normal indivi-
duals (12). Recent studies suggest that themain determi-
nant of nasal mucociliary clearance is ciliary beat
frequency (21). In addition,Graf and Hallen (6) recordeda potentiation of rhinitismedicamentosa in the presence
of BKC.However, patients with rhinitis tend to produce
more mucus, which can have a protective e¡ect against
BKC (11). Storaasetal. (22) showed that sustained admin-
istration of BKC to human nasal mucosa can generate
tolerance without adverse e¡ects. Using healthy sub-
jects, Storaas et al. (22) administered isotonic saline and
BKC (0?1mgml71) acutely to nasal mucosa. At ¢rst the
BKC induced immediate nasal smart or pain (P50?05),





Evidence of Squamous Cell Metaplasia
Using BKC as a preservative in corticosteroid-containing
nasal sprays administered to rats, Berg et al. demon-
strated that BKC may be potentially toxic to the nasal
mucosa in vivo (16). In contrast to the study of Ainge et al.
described above (3), the objective of this study was to
examine the morphological e¡ects of topical nasal ster-
oids in the presence or absence of BKC in di¡erent parts
of the nasal cavities originally covered by histiotypic
respiratory ciliatedmucosa (16).
The study was conducted in 30 rats divided into three
groups and given one of the following: beclomethasone
dipropionate aqueous nasal spray (plus 310mgml71
BKC), £unisolide nasal spray (plus 220mgml71 BKC), or
budesonide (no BKC) aqueous nasal spray. In a separate
experimental set-up, two groups of10 animalswere trea-
ted with either beclomethasone dipropionate or bude-
sonide. The steroid solutions were administered by
spray twice daily for 21 days into the right nostril,
whereas the left nostril received saline deliveredby ami-
cro-pipette. At the conclusion of the treatmentperiod, a
careful morphological study was conducted by cutting
the nose serially in frontal sections of 4mm from the
anterior and posterior parts of the nose.
The strengths of this study included the ability to: (a)
use a rat animalmodelwithrespiratorymucosa devoid of
respiratory tract disease with a similar structure, func-
tion, andmetabolism to that found inhumans; (b) control
the dose and deposition of the drug; (c) investigate the
nasal mucosa in total as opposed to focal biopsies; and
(d) examine the e¡ect of topical steroids with and with-
out BKCversus controls in the same section (16).
In response to beclomethasone and £unisolide nasal
sprays containing BKC, squamous cell metaplasia was
evident primarily in the anterior portion of the nose.
Characteristic of these tissues was a reduced epithelial
cell height with some pleomorphism. In addition, cilia
were rarely found and layers ofmucus were absent.
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that did not contain BKC exhibited no histological di¡er-
ences as compared to saline controls. A thick, pseudo-
strati¢ed epithelium was found on the lateral nasal wall
and the septum. Individual cells were characterized as
having a tall and columnar phenotype and typically dis-
played cilia on their apical surface covered with a layer
of mucus. The submucosal layer was also una¡ected by
budesonide such that the connective tissue, vessels and
submucosal glands appeared normal.
Based on these observations and other studies prov-
ing steroid compounds to be harmless to respiratory
mucosa in vitro (23,24), the data suggest that the ob-
served squamous cell hyperplasia was due to the inclu-
sion of BKC in the steroidal nasal sprays.
In vivoHuman Studies: Aggravation of
Rhinitis Medicamentosa
Graf et al. showed adverse biological e¡ects of BKC in
de¢ning the mechanism responsible for rhinitis medica-
mentosa found in response to overuse of vasoactive de-
congestants (5^7,24^26). Rhinitis medicamentosa is
de¢ned as a condition of nasal hyperreactivity, mucosal
swelling, and tolerance that is also found in response to
vasoactive decongestants as well as other drugs (24,27).
In the case of decongestant-induced rhinitismedicamen-
tosa, inclusion of BKC as a preservative has been shown
to aggravate rhinitis medicamentosa primarily by in-
creasing nasal swelling.
The e¡ect of BKC as a preservative in a decongestant
nasal spray was investigated in a randomized, double-
blind, parallel study with 20 healthy volunteers (5). The
principal aim of the study was to determine whether
the use of BKC in oxymetazoline nasal spray exerts any
e¡ect on the development of rhinitismedicamentosa.
The subjects were divided into two groups that were
treated with oxymetazoline (0?5mgml71) nasal spray
with or without 0.1mg/ml BKC administered three times
daily (0?1mlnostril71) for 30 days.Nasalmucosal swelling
was determinedby rhinostereometry, an optical, direct,
non-invasive method via topographic measurement,
withoutmanipulating the nasal structures (28).Of note,
this method allows one to distinguish between healthy
patients and patients with vasomotor rhinitis who exhi-
bit increased histamine sensitivity (26). Nasal stu⁄ness
was estimated on a visual analogue scale (5).
In healthy volunteers treated with oxymetazoline in
thepresence of BKC for 30 days, a statistically signi¢cant
increase inmucosal swelling (1?14mm) was found in both
inferior conchae.Likewise, bothmorning andevening na-
sal stu⁄ness was elevated in healthy volunteers during 4
weeks of treatment with oxymetazoline and BKC (5). In
fact, a signi¢cant increasewas detected from the second
weekof drug treatment.Furthermore, elevatedmorningand evening stu⁄nesswas signi¢cantly greater than that
observed in patients treated with oxymetazoline alone
as analysed by unpaired t-tests (5).
It should be noted that patients treated with oxyme-
tazoline alone also exhibited signi¢cant increases in mu-
cosal swelling and nasal stu⁄ness indicative of rhinitis
medicamentosaöevents that were aggravated by BKC.
Thus, after 30 days of drug treatment, mucosal swelling
andmean evening estimatednasal stu⁄nesswere signi¢-
cantly greater in patients administered oxymetazoline
with BKCversus oxymetazoline alone.
The detrimental e¡ect of BKC is long-lived, as subse-
quent treatment of patients with the same combination
of drugs led to reduced mucosal swelling in response to
BKC after a 3-month period (7). In this study, the reexpo-
sure to drug treatmentwas limited to10 days.Only those
patients treated with the combination of oxymetazoline
andBKCexhibited a signi¢cant increase innasal stu⁄ness,
apparent from the fourth day onward. Mucosal swelling
was signi¢cantly increased after the10-day reexposure in
the oxymetazoline plus BKC group of patients.
In contrast, thepatients on oxymetazoline alone failed
to show a signi¢cant increase in mucosal swelling. The
mucosal swelling found in the oxymetazoline plus BKC
group was also signi¢cantly greater than that observed
in the oxymetazoline alone group, as determined by an
unpaired t-test. Thus, a nasal decongestant spray com-
posed of vasoactive decongestant and BKC has a long-
term adverse e¡ect on the nasalmucosa (7).
A subsequent study by Graf and Hallen demonstrated
that BKC alone causesmucosal swelling in healthy volun-
teers (6). The objective of this study was to clarify the
e¡ects of BKC since earlier studies implicating the pre-
servative through its aggravation of rhinitis medicamen-
tosa and its long-lasting adverse e¡ect on the nasal
mucosa were limited to inclusion of the preservative
with oxymetazoline (5,7).
In this double-blind placebo-controlled study, 30
volunteers were randomized to receive 0?1ml of either
0?5mgml71 oxymetazoline nasal spray without BKC,
0?1mgml71BKCnasal spray alone, or placebonasal spray
consisting of an aqueous solution of sodium chloride, so-
dium phosphate, and ethylenediamine tetra-acetic acid.
The study drugs were administered three times daily
for1month.Thevariables studied includednasal mucosal
swelling, symptom scores of nasal stu⁄ness, and nasal
reactivity, as determined by histamine challenge.
BKC did not generate nasal stu⁄ness as shown in the
earlier studies for oxymetazoline plus BKC (5). Instead,
the patient group administered oxymetazoline alone
showed elevated nasal stu⁄ness from day 14 onward to
the completion of the study. Nasal reactivity, as assessed
byhistamine challenge,was signi¢cantly increasedbyBKC
after 30 days. However, the increase in nasal reactivity
was not as pronounced as that found in patients adminis-
tered nasal sprays containing oxymetazoline alone.
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nasal mucosal swelling and the estimated stu⁄ness was
found in the BKC group, in contrast to the oxymetazo-
linegroup.The explanationmaybe that after several days
on oxymetazoline, the subjects adjust to breathing easily
through the nose.When the decongestive e¡ect disap-
pears, subjects may experience nasal stu⁄ness without
rebound swelling (i.e. a false or exaggerated sensation of
nasal stu⁄ness).Thismayexplainwhy some subjects ¢nd
it hard to stop using the decongestants within the
recommended time andwhy theyultimately develop rhi-
nitismedicamentosa.
The most outstanding adverse biological event asso-
ciatedwith the administration of BKC involved the swel-
ling of the nasal mucosa after the completion of the
treatment. At the end of treatment, a signi¢cant in-
crease in mucosal swelling was found in the BKC group
(0?67mm) as compared to either the oxymetazoline
group (0?29mm) or the placebo group (0?09mm).
Basedon these ¢ndings, itwas concluded that BKC ag-
gravates decongestant-induced rhinitis medicamentosa
viamucosal swelling (6).However, a possible confounding
factor in this study is that oxymetazoline extends the
duration of contact of BKC with the nasal mucosa (29).
Combined with BKC, oxymetazoline is more likely to
cause rhinitismedicamentosa (29).
SUMMARY
The objective of this articlewas to assess the deleterious
e¡ects of BKC in vivo. Previous studies concluding that
BKC lacks in vivo e¡ects may have been £awed, limiting
the signi¢cance of their ¢ndings. Moreover, the data of
Graf and colleagues, showing that in vivo administration
of BKC aggravates rhinitis medicamentosa in response
to vasoactive decongestant nasal sprays, support the
contrary. In fact, Berg and colleagues also demonstrate
adverse biological e¡ects on rat respiratory mucosa as-
sociated with the use of benzalkonium-containing corti-
costeroid nasal sprays administered in vivo (16).
Further studies of BKC-containing corticosteroid na-
sal sprays in both normal volunteers and patients su¡er-
ing from perennial rhinitis are warranted, particularly
with functional correlates. Further study of the acute
and chronic adverse biologic e¡ects induced by BKC in
patients with rhinitis medicamentosa is also warranted,
as well as the role of pH in BKC toxicity. In lieu of these
data, the use of formulations of corticosteroid-contain-
ing sprays now available that do not include BKC may
avert any potential adverse biological e¡ects.
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